Protein arginine methyltransferase 7 (PRMT7) is the lone member of the type III PRMT family and catalyzes arginine monomethylation, a specific form of arginine methylation. Recent literature positions PRMT7 as an important regulator of multiple cancer‑relevant processes. This review summarizes the enzyme's structural and biochemical characteristics, its reported dysregulation across tumor types, mechanistic roles in tumor biology, and progress toward pharmacologic inhibition with an emphasis on PRMT7‑selective compounds.
PRMT7 is classified biochemically as a type III protein arginine methyltransferase. Its catalytic activity results primarily in monomethylation of arginine residues on substrate proteins. These post‑translational modifications influence chromatin state, transcriptional programs, RNA metabolism and signaling networks. The enzyme's distinct catalytic profile differentiates it from type I and II PRMTs and defines unique substrate and mechanistic spaces for interrogation as a cancer target.
Aberrant PRMT7 expression has been reported in a range of malignancies. The review lists dysregulated PRMT7 in leukemia, breast cancer, lung cancer, renal cell carcinoma, hepatocellular carcinoma, prostate cancer and gastric cancer. Across these tumor types, altered PRMT7 expression correlates with processes that drive malignant phenotypes, suggesting disease‑specific roles and potential as a biomarker or therapeutic target. The review notes that the functional consequences of PRMT7 dysregulation are context dependent and may differ by tumor lineage and cellular state.
PRMT7 contributes to tumor biology through several mechanistic avenues, including epigenetic regulation, transcriptional control, RNA processing and modulation of signaling pathways. These mechanisms underpin phenotypes observed in experimental systems and reported across tumor types.
The review highlights a role for PRMT7 in epithelial‑mesenchymal transition (EMT), a process linked to increased motility and invasive potential. Through epigenetic and transcriptional regulation, PRMT7 has been implicated in driving EMT programs in some contexts, thereby promoting cellular behaviors associated with metastasis. The authors emphasize that effects on EMT and metastatic capacity can be variable depending on cellular and tumor context.
PRMT7 has been associated with features of cancer stemness in several malignancies. By influencing transcriptional networks and RNA processing, PRMT7 activity can contribute to self‑renewal phenotypes and cellular hierarchies that support tumor initiation and therapeutic resistance. The review frames cancer stemness as one of the functional outputs of PRMT7‑mediated regulation.
The review also addresses PRMT7's contributions to immune modulation. PRMT7 activity can influence pathways relevant to tumor‑immune interactions, although the direction and magnitude of immune effects are context dependent. The authors note immune modulation among the functional roles that may render PRMT7 an actionable node for combination strategies targeting both tumor cells and the microenvironment.
Given its multifaceted roles in cancer biology, PRMT7 has attracted interest as a molecular target. The review summarizes recent advances in PRMT inhibitor development and highlights several PRMT7‑selective compounds that have emerged: SGC3027, SGC8158 and JS1310. These agents represent progress toward chemical tools and potential therapeutic leads that selectively engage PRMT7's enzymatic activity. The review emphasizes selective PRMT7 inhibition as an area of active investigation.
Although promising, translation of PRMT7 biology into therapies faces key challenges. The review identifies the need to: delineate context‑specific functions and substrates of PRMT7 across tumor types; define which cancer settings are most dependent on PRMT7 activity; and address issues related to inhibitor selectivity, on‑target effects, and therapeutic window. The authors stress that understanding PRMT7's varied roles in different cellular contexts is essential to exploiting targetable vulnerabilities and advancing precision approaches.
PRMT7 is a distinct arginine methyltransferase with emerging importance in cancer progression through epigenetic, transcriptional, RNA‑processing and signaling mechanisms. Dysregulation has been observed across multiple malignancies, and functional links to EMT, stemness, metastasis and immune modulation make PRMT7 a compelling candidate for targeted intervention. Recent development of PRMT7‑selective compounds such as SGC3027, SGC8158 and JS1310 marks progress toward pharmacologic modulation, but further work to clarify context‑specific biology and translational challenges is required. Elucidating PRMT7's targetable vulnerabilities may create new avenues for precision cancer therapy.